Package Leaflet: Information for the User
Solinitrina Fuerte 5 mg/ml Solution for Injection
Nitroglycerin
Read all of this leaflet carefully before you start taking this medicine.
Contents of the Package Leaflet:
Solinitrina Fuerte is a medicine administered as a solution for intravenous infusion AFTER DILUTION and is presented in a package containing 12 ampoules.
The active ingredient, nitroglycerin, belongs to the group of drugs called nitrites and related substances.
This medicine is used in the following cases:
Do not use Solinitrina Fuerte
Be careful with Solinitrina Fuerte
Consult your doctor, even if any of the above circumstances have occurred to you in the past.
Use of other medicines
Tell your doctor or pharmacist if you are using, or have recently used, any other medicines, including those obtained without a prescription.
Note that these instructions may also apply to medicines that have been taken/used before or may be taken/used after.
Pregnancy and breastfeeding
Pregnancy
If you are, or think you may be, pregnant, or if you plan to become pregnant, you should inform your doctor, who will decide whether it is convenient for you to receive Solinitrina.
Consult your doctor or pharmacist before using any medicine.
Breastfeeding
It is unknown whether nitroglycerin is excreted in breast milk. The risk to newborns/children cannot be excluded.
Consult your doctor or pharmacist before using any medicine.
Driving and using machines
Solinitrina may cause flushing, dizziness, or decreased blood pressure, especially at the start of treatment. If you experience any of these effects, avoid driving or using machines.
The amount of alcohol in this medicine may impair your ability to drive or use machinery.
Important information about some of the components of Solinitrina Fuerte
The presence of ethanol may be a risk factor in patients with liver disease, alcoholism, epilepsy, pregnant women, and children.
This medicine contains 100% (10 ml) of ethanol (alcohol), which corresponds to 8.4 g of ethanol per ampoule, approximately equivalent to 210 ml of beer or 90 ml of wine.
This medicine is harmful to people with alcoholism.
The alcohol content should be taken into account in the case of pregnant or breastfeeding women, children, and high-risk populations, such as patients with liver disease or epilepsy.
The amount of alcohol in this medicine may alter the effects of other medicines.
The amount of alcohol in this medicine may impair your ability to drive or use machinery.
Solinitrina Fuerte is a hospital medicine.
This medication should be administered by your doctor or nurse.
Solinitrina Fuerte is a solution for intravenous infusion.
THIS PREPARATION SHOULD NEVER BE INJECTED DIRECTLY.
It should be diluted beforehand in 5% glucose (dextrose) or physiological saline solution (0.9% sodium chloride).
The dissolution of one 50 mg ampoule in 100 ml gives a concentration of 500 mcg/ml.
A solution of 400 mcg/ml or less is recommended, depending on the planned dose.
The usual dose for adults is 10-200 mcg/min. It is recommended to start the infusion at a low level and gradually increase it until the desired effect is achieved. In some surgical interventions, doses of 400 mcg/min or higher may be necessary.
During administration, clinical evaluation and frequent blood pressure measurements should be performed. Whenever possible, measures of pulmonary artery wedge pressure or cardiac output should be used to adjust the dose to the patient's needs.
If possible, a infusion pump or other suitable microdosing device (made of rigid plastic) should be used to ensure correct dosing.
Indicatively, the following dosage guidelines are suggested:
Surgery:
Although most patients respond to doses of 100-200 mcg/min, in some surgical interventions, doses higher than 400 mcg/min have been necessary. In the treatment of preoperative myocardial ischemia, the recommended dose is 15-20 mcg/min, increasing by 10-15 mcg/min until the desired response is achieved.
If you think the action of Solinitrina Fuerte is too strong or too weak, inform your doctor.
Your doctor will indicate the duration of your treatment with Solinitrina Fuerte. Do not stop treatment before, as a possible withdrawal reaction may occur.
Guidelines for correct administration:
It should be taken into account that nitroglycerin is absorbed by many types of plastic, and therefore the solution should always be made in a GLASS CONTAINER. It is possible that certain plastic containers (polyethylene) are compatible with the solution, but containers made of polyvinyl chloride can absorb 40-80% of the nitroglycerin and should be avoided absolutely.
Since most infusion equipment is made using polyvinyl chloride tubing, there will be a variable degree of absorption, and the concentration in the vial will not coincide with that received by the patient. For this reason, it is essential that the dosage be adjusted according to the clinical response.
There are special infusion equipment on the market made of material that does not absorb nitroglycerin. If these devices are used, it should be taken into account that, since most clinical experiences have been carried out with standard polyvinyl chloride equipment, the application of standard dosage guidelines may result in excessively high responses. It is necessary to be extremely careful when adjusting the dose.
If you are given more Solinitrina Fuerte than you should
The medicine should be administered by your doctor/nurse. In the unlikely event that you receive an excessive amount of nitroglycerin, you may experience some of the undesirable effects listed below: flushing of the face and neck, dizziness, hypotension, tachycardia, and headache.
Your doctor/nurse will initiate symptomatic and supportive treatment.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medicine and the amount injected.
Like all medicines, Solinitrina Fuerte can cause side effects, although not everyone gets them.
It can cause headaches that usually disappear after a few days. This headache can be treated with analgesics, although it may be necessary to reduce the dose or interrupt treatment. Other side effects that may occur are flushing, nausea, dizziness, hypotension, and tachycardia. Vomiting and bluish discoloration of the skin have been occasionally described.
If you think any of the side effects you are experiencing is serious, or if you notice any other side effects not mentioned in this leaflet, inform your doctor or pharmacist.
Reporting of side effects
If you experience any type of side effect, consult your doctor, even if it is a possible side effect not listed in this leaflet. You can also report them directly through the Spanish Medicines Monitoring System https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
The solvent is volatile, and precautions should be taken to avoid the formation of concentrated nitroglycerin. Do not leave open, unused ampoules. The contents should be discarded with plenty of running water. In case of breakage of the ampoules or accidental spillage of the contents, clean immediately with a cloth dampened in a slightly alkaline solution.
No special storage conditions are required.
Do not use Solinitrina Fuerte after the expiration date stated on the packaging after "CAD". The expiration date is the last day of the month indicated.
Medicines should not be disposed of via wastewater or household waste. Deposit the packaging and any unused medicines in the pharmacy's SIGRE collection point. If in doubt, ask your pharmacist how to dispose of the packaging and any unused medicines. This will help protect the environment.
Composition of Solinitrina Fuerte
Appearance of the product and packaging contents
A package containing 12 amber glass ampoules of 10 ml.
Kern Pharma, S.L.
Venus, 72 - Pol. Ind. Colón II
08228 Terrassa - Barcelona
Spain
Manufacturer
Kern Pharma, S.L.
Venus, 72 - Pol. Ind. Colón II
08228 Terrassa - Barcelona
Spain
or
INDUSTRIAS FARMACEUTICAS ALMIRALL PRODESFARMA, S.L.
Ctra. Nacional II, Km. 593
Sant Andreu de la Barca 08740 Spain
or
Ronda de Los Olivares, parcela 11. Polígono Industrial Los Olivares
23009 Jaén Spain
This leaflet was approved in June 2011.
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es